Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.

FDA approved background, 3D rendering, blue street sign

US FDA approval of Sanofi/Regeneron Pharmaceuticals Inc's PD-1 inhibitor Libtayo (cemiplimab-rwlc) in a niche market for cutaneous squamous cell carcinoma (CSCC) paves the way for development across a range of other indications as well for the partners' immuno-oncology strategy more generally.

FDA approved Libtayo on Sept. 28 for locally advanced squamous cell carcinoma (CSCC) in patients who are not candidates fur...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip